Chris Viehbacher, Biogen CEO (Photo by Suzanne Kreiter/The Boston Globe via Getty Images)
September 28, 2023 10:42 AM EDTUpdated September 30, 01:04 AM
Health Tech

Bio­gen’s R&D prun­ing hits dig­i­tal health as biotech scraps 23,000-per­son cog­ni­tive study with Ap­ple

Kyle LaHucik

Senior Reporter

Bio­gen axed its 23,000-per­son cog­ni­tive health study with Ap­ple phones and watch­es last week as part of a broad­er pull­back in the biotech’s fledg­ling dig­i­tal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times